Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
clinical trials
drugs
3
×
life sciences
national blog main
boston blog main
boston top stories
fda
onpattro
patisiran
acute hepatic porphyrias
akcea therapeutics
akin akinc
alnylam pharmaceuticals
aminolevulinic acid
anylam pharmaceuticals
boston
cannabidiol
cardiomyopathy
dravet syndrome
epidiolex
fen-phen
fenfluramine
givosiran
gw pharmaceuticals
inotersen
lennox-gastaut syndrome
national top stories
neuropathy
new york
new york blog main
new york top stories
paul matteis
pfizer
rna interference
san diego blog main
san diego top stories
san francisco
san francisco blog main
san francisco top stories
stifel financial
What
ago
3
×
drug
3
×
fda
alnylam
approved
battle
medicine
pharmaceuticals
rare
sets
weeks
akcea
amyloidosis
approval
attr
available
cannabis
data
debilitating
derivative
disease
epilepsy
form
genetic
gw
gw’s
indicated
interference
marijuana
market
medicines
nod
oks
patients
pfizer
quick
rna
rnai
second
seek
Language
Current search:
drug
×
drugs
×
ago
×
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug